RBC raises Biogen's price target as pipeline prospects come into focus

RBC Capital Markets raises Biogen's BIIB.O price target to $213 from $205

New PT implies a 68.6% upside to the stock's last close

Brokerage says Biogen is approaching a catalyst-rich period with late-stage trial results expected from 2026 to 2028 for key drugs in rare kidney diseases, lupus, and Alzheimer's

RBC believes there isn't one huge drug that will determine the company's fate, but rather several promising candidates, which spreads out the risk

If all the drugs in the company's development pipeline succeed, the stock could rise by as much as 40%, brokerage says

As of last close, BIIB stock down 17.4% YTD